Oxford-based AI healthtech company developing automated medical imaging platforms (Brainomix 360 Stroke and e-Lung) to support stroke assessment and detect/track pulmonary fibrosis with FDA-cleared products used in over 20 countries.
Investment Rounds
Capital activity and funding progression
| Amount | Date | Round |
|---|---|---|
| £4.8 M | Feb, 2026 | series-c |
Frequently Asked Questions
Where is Brainomix located?
Brainomix is located in Oxford, United Kingdom.
What industries does Brainomix operate in?
Brainomix operates in the following industries: healthcare, medical imaging, artificial intelligence, healthtech.
How much total funding has Brainomix raised?
Brainomix has raised a total of $4,800,000.
Who are the investors in Brainomix?
The investors in Brainomix are: IP Group Hostplus Innovation Fund, Returning investors, Unnamed U.S. investor.
What is Brainomix?
Brainomix is a leading medical imaging company that develops artificial intelligence software to assist clinicians in making faster and more accurate treatment decisions for patients with stroke, lung disease, and cancer.
How does the Brainomix 360 platform assist in stroke care?
The Brainomix 360 platform uses state-of-the-art AI algorithms to automatically interpret brain scans, helping physicians identify eligible patients for life-saving treatments like mechanical thrombectomy more quickly.
Where is Brainomix headquartered?
Brainomix is based in Oxford, United Kingdom, and was originally established as a spin-out from the University of Oxford.
What medical conditions does Brainomix technology address?
While initially focused on stroke, the company has expanded its AI imaging solutions to support the diagnosis and monitoring of interstitial lung disease and various oncological conditions.
Is Brainomix software used globally?
Yes, the AI solutions developed by the company are deployed in hundreds of hospitals across many countries, supporting healthcare providers worldwide in improving patient outcomes through automated image analysis.